Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M807Revenue (TTM) $M6.9Net Margin (%)-2,409.2Altman Z-Score-10.0
Enterprise Value $M726EPS (TTM) $-1.3Operating Margin %-2,409.4Piotroski F-Score3
P/E(ttm)--Beneish M-Score-7.3Pre-tax Margin (%)-2,409.2Higher ROA y-yY
Price/Book--10-y EBITDA Growth Rate %-3.9Quick Ratio6.6Cash flow > EarningsY
Price/Sales1175-y EBITDA Growth Rate %-1.6Current Ratio6.6Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-127.8Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M132ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with ZIOP

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
Current Price Change from Average Comment Current Shares

ZIOP is held by these investors:

ZIOP: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BELBEL CAESAR JCOO, CLO, and Secretary 2015-11-19Sell153,333$12.84-52.49view
LEBEL FRANCOISExecutive Vice President R&D 2015-06-09Sell50,000$10.12-39.72view
BRENNAN MURRAYDirector 2015-06-04Sell40,000$9.7-37.11view
Lafond Kevin GVice Pres., Treasurer, & CAO 2015-06-03Sell57,500$9.65-36.79view
KIRK RANDAL JDirector, 10% Owner 2015-02-09Buy1,440,000$8.75-30.29view
KIRK RANDAL JDirector, 10% Owner 2013-10-29Buy2,857,143$3.574.29view
KIRK RANDAL JDirector, 10% Owner 2012-01-20Buy1,923,075$5.217.31view
KIRK RANDAL JDirector, 10% Owner 2011-08-23Buy38,294$4.9922.24view
KIRK RANDAL JDirector, 10% Owner 2011-08-22Buy461,646$4.9223.98view
Fowler WycheDirector 2011-08-10Buy5,000$5.1917.53view

Quarterly/Annual Reports about ZIOP:

News about ZIOP:

Articles On GuruFocus.com
Intrexon Corp is expanding his business Jun 25 2015 
Hayman Advisors Update - Second Quarter Sells and Company Results Aug 26 2013 
Bass’ New Buy – ZIOPHARM Oncology Inc. May 16 2013 
The Far-Off Four, 52-week Lows Held by Gurus May 11 2013 

More From Other Websites
ZIOPHARM ONCOLOGY INC Financials Feb 22 2017
ZIOPHARM Oncology, Inc. :ZIOP-US: Earnings Analysis: Q4, 2016 By the Numbers : February 22, 2017 Feb 22 2017
Ziopharm 4Q Loss 11 Cents a Share Vs 7c Last Year Feb 17 2017
Ziopharm reports 4Q loss Feb 16 2017
Ziopharm reports 4Q loss Feb 16 2017
ZIOPHARM ONCOLOGY INC Files SEC form 10-K, Annual Report Feb 16 2017
ZIOPHARM Reports Fourth-Quarter 2016 Financial Results and Provides Update on Recent Activities Feb 16 2017
6 Hot Stocks Among Shorts: IBM, Exxon Mobil And More Jan 31 2017
ZIOPHARM Utilizing Non-Viral Sleeping Beauty Platform to Rapidly Produce CAR-Expressing T cells... Jan 31 2017
Biotech M&A Activity Expected to Rise in 2017: Latest Reports on Tenax Therapeutics and ZIOPHARM... Jan 30 2017
6 Hot Stocks Among Shorts: Weight Watchers Moves Ahead Of The Pack Jan 24 2017
ZIOPHARM ONCOLOGY INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jan 11 2017
ZIOPHARM ONCOLOGY INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jan 10 2017
ZIOPHARM and Intrexon Announce Cooperative Research and Development Agreement with the National... Jan 10 2017
Exclusive: Ziopharm CEO Talks Partnerships, Balance Sheet And JPM Healthcare Conference Presentation Jan 09 2017
ZIOPHARM to Present at the 35th Annual J.P. Morgan Healthcare Conference Jan 04 2017
Implied Volatility Surging for ZIOPHARM Oncology (ZIOP) Stock Options Jan 03 2017
ZIOPHARM Oncology, Inc. – Value Analysis (NASDAQ:ZIOP) : December 23, 2016 Dec 23 2016
ETFs with exposure to ZIOPHARM Oncology, Inc. : December 22, 2016 Dec 22 2016
ZIOPHARM Oncology, Inc. breached its 50 day moving average in a Bearish Manner : ZIOP-US : December... Dec 22 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)